Literature DB >> 12799035

Antigen loading of dendritic cells with whole tumor cell preparations.

Peter Thumann1, Isabelle Moc, Jens Humrich, Thomas G Berger, Erwin S Schultz, Gerold Schuler, Lars Jenne.   

Abstract

Dendritic cells (DC) based vaccinations have been widely used for the induction of anti-tumoral immunity in clinical studies. Antigen loading of DC with whole tumor cell preparations is an attractive method whenever tumor cell material is available. In order to determine parameters for the loading procedure, we performed dose finding and timing experiments. We found that apoptotic and necrotic melanoma cells up to a ratio of one-to-one, equivalent to 1mg/ml protein per 1 x 10(6) DC, can be added to monocyte derived DC without effecting DC recovery extensively. Using the isolated protein content of tumor cells (lysate) as a parameter, up to 5 mg/ml protein per 1 x 10(6) DC can be added. To achieve significant protein uptake at least 1 mg/ml of protein have to be added for more than 24 h as tested with FITC-labelled ovalbumin. Maturation inducing cytokines can be added simultaneously with the tumor cell preparations to immature DC without affecting the uptake. Furthermore, we tested the feasibility of cryopreservation of loaded and matured DC to facilitate the generation of ready to use aliquots. DC were cryopreserved in a mix of human serum albumin, DMSO and 5% glucose. After thawing, surface expression of molecules indicating the mature status (CD83, costimulatory and MHC molecules), was found to be unaltered. Furthermore, cryopreserved DC kept the capability to stimulate allogenic T-cell proliferation in mixed leukocyte reactions at full level. Loaded and matured DC pulsed with influenza matrix peptide (IMP) retained the capacity to induce the generation of IMP-specific cytotoxic T-lymphocytes after cryopreservation as measured by ELISPOT and tetramer staining. The expression of the chemokine receptor CXCR-4 and CCR-7 remained unaltered during cryopreservation and the migratory responsiveness towards MIP-3beta was unaltered as measured in a migration assay. Thus we conclude that the large scale loading and maturation of DC with whole tumor cell preparations can be performed in a single session. These data will facilitate the clinical application of DC loaded with whole tumor cell preparations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12799035     DOI: 10.1016/s0022-1759(03)00102-9

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  18 in total

1.  Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.

Authors:  Susanne M Rittig; Maik Haentschel; Katrin J Weimer; Annkristin Heine; Martin R Muller; Wolfram Brugger; Marius S Horger; Olga Maksimovic; Arnulf Stenzl; Ingmar Hoerr; Hans-Georg Rammensee; Tobias A W Holderried; Lothar Kanz; Steve Pascolo; Peter Brossart
Journal:  Mol Ther       Date:  2010-12-28       Impact factor: 11.454

2.  Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles.

Authors:  Hong Shen; Anne L Ackerman; Virginia Cody; Alessandra Giodini; Ella R Hinson; Peter Cresswell; Richard L Edelson; W Mark Saltzman; Douglas J Hanlon
Journal:  Immunology       Date:  2006-01       Impact factor: 7.397

Review 3.  Directing dendritic cell immunotherapy towards successful cancer treatment.

Authors:  Rachel Lubong Sabado; Nina Bhardwaj
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

4.  Static image analysis as new approach for the characterization of tumor cell lysate used in dendritic cell vaccine preparation.

Authors:  Isabelle Müller; Dorothee Hartmann; Joachim Oertel; Cornelia M Keck; Hermann Eichler
Journal:  Transfus Med Hemother       Date:  2015-01-29       Impact factor: 3.747

5.  The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity.

Authors:  S Greiner; J Y Humrich; P Thuman; B Sauter; G Schuler; L Jenne
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

6.  Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy.

Authors:  Robert M Prins; Horacio Soto; Vera Konkankit; Sylvia K Odesa; Ascia Eskin; William H Yong; Stanley F Nelson; Linda M Liau
Journal:  Clin Cancer Res       Date:  2010-12-06       Impact factor: 12.531

7.  Targeted delivery of amikacin into granuloma.

Authors:  Ana Montes-Worboys; Scott Brown; Doron Regev; Brendan F Bellew; Kamal A Mohammed; Ibrahim Faruqi; Parvesh Sharma; Brij Moudgil; Veena B Antony
Journal:  Am J Respir Crit Care Med       Date:  2010-08-06       Impact factor: 21.405

Review 8.  Dendritic cells based immunotherapy.

Authors:  Na Shang; Matteo Figini; Junjie Shangguan; Bin Wang; Chong Sun; Liang Pan; Quanhong Ma; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2017-10-01       Impact factor: 6.166

9.  Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients.

Authors:  Robert M Prins; Xiaoyan Wang; Horacio Soto; Emma Young; Dominique N Lisiero; Brendan Fong; Richard Everson; William H Yong; Albert Lai; Gang Li; Timothy F Cloughesy; Linda M Liau
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

10.  Enhancement of anti-lymphoma immuno-effects mediated by dendritic cells pulsed with heat-stressed and rituximab-coated CD20+ lymphoma cells.

Authors:  Limei Ai; Hanyun Ren; Yongjin Shi; Yujun Dong
Journal:  Int J Hematol       Date:  2008-04-15       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.